

# Overcoming hurdles to cancer immune response: cell therapies, cancer vaccine development and combination therapies

*Returning on the 27th & 28th September 2017 for strategic direction on preclinical development of vaccines and new approaches.*

LONDON, UNITED KINGDOM, April 27, 2017 /EINPresswire.com/ -- SMI Reports: Widely recognised as one of the most profitable areas of drug development, the global market for [cancer vaccines](#) is expected to grow at a CAGR of 27% by 2019.\* With revolutionary cancer treatments on the horizon, Cancer Vaccines 2017 returns to London this September to showcase the latest updates in vaccine development and targeted immuno-therapies.

Returning on the 27th & 28th September 2017 for strategic direction on preclinical development of vaccines and new approaches to enhancing cancer vaccine efficacy to enable those in attendance to overcome hurdles to cancer immune response.

This year's two day conference is guaranteed to deliver the key requirements and tools for successful vaccine development through informed guidance delivered by a high level of speakers, including Vaccibody, Genentech, Exicure, MSD, Agenus, ImmuniTrack and more.

Whilst inspiration and education are high on the 2017 agenda, delegates should be prepared to engage and participate with interactive panel discussions, case studies and more sharing of expertise than ever before.

We are excited to highlight some of the noteworthy features of this year's programme:

- In depth case study examples of peptide, DNA, neoantigen and MHC based vaccine development with INSERM
- Maximise the therapeutic potential of cancer vaccines in combination with checkpoint inhibitors with MSD
- Explore personalising cancer vaccines, characterising and applying the outside in approach in cancer vaccine development with Northwest Biotherapeutics



- Hear 1st hand experience on strategies for designing and developing successful cancer vaccines presented by Vaccibody
- Develop RNA-based vaccines and optimise their efficacy with industry leaders Onyvax
- Attend our spotlight session on Structural and biophysical bases for the induction of efficient CTL responses against cancer-associated neoantigens with Karolinska Institute

This is just a snapshot of what will be covered at Cancer Vaccines 2017! For further information please visit <http://www.cancervaccineevent.com/ein>

There is currently a £300 early bird discount for all registrations made before 31st May.

6th Cancer Vaccines Conference  
27th – 28th September 2017  
London, UK  
[www.cancervaccineevent.com/ein](http://www.cancervaccineevent.com/ein)

Follow the conversation on Twitter and LinkedIn at #cacnervac17

\*Source: <http://bit.ly/2omQbRI>

Kyra Williams  
SMi Group Ltd  
+44 (0)20 7827 6012  
email us here

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2017 IPD Group, Inc. All Right Reserved.